The Peter Attia Drive Podcast Por Peter Attia MD arte de portada

The Peter Attia Drive

The Peter Attia Drive

De: Peter Attia MD
Escúchala gratis

The Peter Attia Drive will feature guests and experts that will offer advice and insight to help you optimize performance, health, longevity, critical thinking, and life. It's hosted by Stanford M.D., TED speaker, and longevity expert Dr. Peter Attia, founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City.Copyright © Peter Attia, MD Actividad Física, Dietas y Nutrición Ejercicio y Actividad Física Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • #387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

    #387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field
    Apr 13 2026
    View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];Other popular "gray market" peptides and why they mostly fail when under scrutiny [1:11:15];How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; andMore. Connect With Peter on Twitter, Instagram, Facebook and YouTube
    Más Menos
    22 m
  • #386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance

    #386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance
    Apr 6 2026

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter's Weekly Newsletter

    In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.

    We discuss:

    • Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];
    • How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];
    • The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];
    • The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];
    • Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];
    • The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];
    • The DO-HEALTH study results: findings, takeaways, and open questions [27:45];
    • The DunedinPACNI study: how the model was developed and what it may add to the field [35:00];
    • The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00];
    • Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and
    • More.

    Connect With Peter on Twitter, Instagram, Facebook and YouTube
    Más Menos
    56 m
  • #385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more

    #385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more
    Mar 23 2026

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter's Weekly Newsletter

    In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines.

    If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

    We discuss:

    • Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance [1:30];
    • How health priorities and training strategies should evolve from early adulthood through older age [2:45];
    • Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00];
    • Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00];
    • How to use wearable data effectively: when it's helpful, when it's not, and how to avoid over-reliance [19:00];
    • DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00];
    • Best practices for building sustainable health habits [30:15];
    • How to train your balance and stability [33:30];
    • How to recover from injuries and use setbacks to build strength and resilience [36:15];
    • High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30];
    • Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00];
    • How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and
    • More.

    Connect With Peter on Twitter, Instagram, Facebook and YouTube
    Más Menos
    19 m
Todas las estrellas
Más relevante
Remarkable podcast with so much valuable information on how to live our best life.

so grateful..

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
As usual learned a lot.
Can't wait for the next episode.
Three more words.

Love!

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
I've been listening to Peter's podcast for a while now. I also read his book. It helped me improve my overall health and become a better version of myself. Thank you so much for everything you do for the community and the world!

Incredible podcast!

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
I get so much out of Peter Attia. Thanks so much for doing all this.

Very informative

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
Reminded me of the importance of exercise. Thank you for this experience. Very helpful and insightful.

Helpful

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
Ver más opiniones